恩华药业(002262) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥1,357,565,651.12, representing a 15.16% increase compared to ¥1,178,806,488.43 in the same period last year[3] - Net profit attributable to shareholders was ¥265,282,248.03, up 16.64% from ¥227,429,413.46 year-on-year[3] - Net profit for Q1 2024 was ¥264,638,776.41, up 17.5% from ¥225,173,396.19 in Q1 2023[15] - Operating profit for the quarter was ¥304,871,280.84, a rise of 16.6% from ¥261,579,559.01 in the same quarter last year[15] - The total comprehensive income for Q1 2024 was ¥264,638,776.41, compared to ¥225,173,396.19 in Q1 2023, reflecting a growth of 17.5%[15] Cash Flow - The net cash flow from operating activities decreased by 35.90%, amounting to ¥233,582,275.30 compared to ¥364,395,839.44 in the previous year[3] - The cash outflow from operating activities totaled CNY 1,232,818,489.41, an increase of 20.9% from CNY 1,019,601,827.61 in the previous period[17] - The cash inflow from sales of goods and services is CNY 1,437,966,302.56, an increase of 5.4% from CNY 1,364,465,949.94 in the previous period[17] - The cash outflow for purchasing goods and services is CNY 343,920,750.51, an increase of 15.2% compared to CNY 298,419,576.07 in the previous period[17] - The cash outflow for taxes paid is CNY 208,319,468.23, an increase of 32.6% from CNY 157,069,102.72 in the previous period[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,603,954,816.16, a 3.76% increase from ¥7,328,195,368.67 at the end of the previous year[3] - The total assets of Jiangsu Enhua Pharmaceutical Co., Ltd. reached CNY 7,603,954,816.16 at the end of the first quarter, an increase from CNY 7,328,195,368.67 at the beginning of the period[11] - The total liabilities of the company were CNY 929,208,374.37, a slight increase from CNY 918,087,703.29, reflecting a growth of approximately 1.2%[12] - The total current liabilities amounted to CNY 823,477,079.03, slightly up from CNY 814,027,830.97, showing an increase of approximately 1.8%[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,628, with the largest shareholder holding 31.77% of the shares[8] - The equity attributable to shareholders of the parent company increased to ¥6,699,423,735.51, up from ¥6,434,141,487.48, marking a growth of 4.1%[13] - The total equity attributable to shareholders increased by 4.12%, reaching ¥6,699,423,735.51 compared to ¥6,434,141,487.48 at the end of the previous year[3] Research and Development - R&D expenses increased by 30.77%, indicating a significant rise in investment in research and development activities[7] - Research and development expenses increased to ¥143,419,925.68, representing a 30.8% rise from ¥109,676,566.12 in the previous year[14] Investment Income - The company recorded a total of ¥6,725,654.77 in investment income from financial products, reflecting effective cash management strategies[5] - The cash inflow from investment income is CNY 6,725,654.77, a decrease of 40.5% from CNY 11,360,194.34 in the previous period[18] Inventory and Receivables - Trade receivables increased to CNY 1,117,797,379.75, up from CNY 1,034,736,344.97, indicating a growth of about 8%[11] - The inventory decreased to CNY 578,955,190.48 from CNY 628,637,457.97, representing a decline of approximately 7.9%[11]